Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
Puma Biotechnology, Inc. announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma...
United States Fayem Johnson International Conference On Molecular Department Of Thoracic Head Neck Medical Oncology Division Of Cancer Medicine University Of Texas Md Anderson Cancer Center
Source: marketscreener.com